Cargando…

Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute

Objectives. The purpose of this retrospective evaluation of advanced-stage ovarian cancer patients was to compare outcome with published findings from other centers and to discuss future options for the management of advanced ovarian carcinoma patients. Methods. A retrospective series of 340 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Marszalek, Anne, Alran, Séverine, Scholl, Suzy, Fourchotte, Virginie, Plancher, Corinne, Rosty, Christophe, Meyniel, Jean Philippe, De Margerie, Vincent, Dorval, Thierry, De La Rochefordière, Anne, Cottu, Paul, Petrow, Peter, Sastre-Garrau, Xavier, Salmon, Rémy Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265260/
https://www.ncbi.nlm.nih.gov/pubmed/22312486
http://dx.doi.org/10.1155/2010/214919
_version_ 1782222062392180736
author Marszalek, Anne
Alran, Séverine
Scholl, Suzy
Fourchotte, Virginie
Plancher, Corinne
Rosty, Christophe
Meyniel, Jean Philippe
De Margerie, Vincent
Dorval, Thierry
De La Rochefordière, Anne
Cottu, Paul
Petrow, Peter
Sastre-Garrau, Xavier
Salmon, Rémy Jacques
author_facet Marszalek, Anne
Alran, Séverine
Scholl, Suzy
Fourchotte, Virginie
Plancher, Corinne
Rosty, Christophe
Meyniel, Jean Philippe
De Margerie, Vincent
Dorval, Thierry
De La Rochefordière, Anne
Cottu, Paul
Petrow, Peter
Sastre-Garrau, Xavier
Salmon, Rémy Jacques
author_sort Marszalek, Anne
collection PubMed
description Objectives. The purpose of this retrospective evaluation of advanced-stage ovarian cancer patients was to compare outcome with published findings from other centers and to discuss future options for the management of advanced ovarian carcinoma patients. Methods. A retrospective series of 340 patients with a mean age of 58 years (range: 17–88) treated for FIGO stage III and IV ovarian cancer between January 1985 and January 2005 was reviewed. All patients had primary cytoreductive surgery, without extensive bowel, peritoneal, or systematic lymph node resection, thereby allowing initiation of chemotherapy without delay. Chemotherapy consisted of cisplatin-based chemotherapy in combination with alkylating agents before 2000, whereas carboplatin and paclitaxel regimes were generally used after 1999-2000. Overall survival and disease-free survival were analyzed by the Kaplan-Meier method and the log-rank test. Results. With a mean followup of 101 months (range: 5 to 203), 280 events (recurrence or death) were observed and 245 patients (72%) had died. The mortality and morbidity related to surgery were low. The main prognostic factor for overall survival was postoperative residual disease (P < .0002), while the main prognostic factor for disease-free survival was histological tumor type (P < .0007). Multivariate analysis identified three significant risk factors: optimal surgery (RR = 2.2 for suboptimal surgery), menopausal status (RR = 1.47 for postmenopausal women), and presence of a taxane in the chemotherapy combination (RR = 0.72). Conclusion. These results confirm that optimal surgery defined by an appropriate and comprehensive effort at upfront cytoreduction limits morbidity related to the surgical procedure and allows initiation of chemotherapy without any negative impact on survival. The impact of neoadjuvant chemotherapy to improve resectability while lowering the morbidity of the surgical procedure is discussed.
format Online
Article
Text
id pubmed-3265260
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32652602012-02-06 Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute Marszalek, Anne Alran, Séverine Scholl, Suzy Fourchotte, Virginie Plancher, Corinne Rosty, Christophe Meyniel, Jean Philippe De Margerie, Vincent Dorval, Thierry De La Rochefordière, Anne Cottu, Paul Petrow, Peter Sastre-Garrau, Xavier Salmon, Rémy Jacques Int J Surg Oncol Clinical Study Objectives. The purpose of this retrospective evaluation of advanced-stage ovarian cancer patients was to compare outcome with published findings from other centers and to discuss future options for the management of advanced ovarian carcinoma patients. Methods. A retrospective series of 340 patients with a mean age of 58 years (range: 17–88) treated for FIGO stage III and IV ovarian cancer between January 1985 and January 2005 was reviewed. All patients had primary cytoreductive surgery, without extensive bowel, peritoneal, or systematic lymph node resection, thereby allowing initiation of chemotherapy without delay. Chemotherapy consisted of cisplatin-based chemotherapy in combination with alkylating agents before 2000, whereas carboplatin and paclitaxel regimes were generally used after 1999-2000. Overall survival and disease-free survival were analyzed by the Kaplan-Meier method and the log-rank test. Results. With a mean followup of 101 months (range: 5 to 203), 280 events (recurrence or death) were observed and 245 patients (72%) had died. The mortality and morbidity related to surgery were low. The main prognostic factor for overall survival was postoperative residual disease (P < .0002), while the main prognostic factor for disease-free survival was histological tumor type (P < .0007). Multivariate analysis identified three significant risk factors: optimal surgery (RR = 2.2 for suboptimal surgery), menopausal status (RR = 1.47 for postmenopausal women), and presence of a taxane in the chemotherapy combination (RR = 0.72). Conclusion. These results confirm that optimal surgery defined by an appropriate and comprehensive effort at upfront cytoreduction limits morbidity related to the surgical procedure and allows initiation of chemotherapy without any negative impact on survival. The impact of neoadjuvant chemotherapy to improve resectability while lowering the morbidity of the surgical procedure is discussed. Hindawi Publishing Corporation 2010 2010-07-25 /pmc/articles/PMC3265260/ /pubmed/22312486 http://dx.doi.org/10.1155/2010/214919 Text en Copyright © 2010 Anne Marszalek et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Marszalek, Anne
Alran, Séverine
Scholl, Suzy
Fourchotte, Virginie
Plancher, Corinne
Rosty, Christophe
Meyniel, Jean Philippe
De Margerie, Vincent
Dorval, Thierry
De La Rochefordière, Anne
Cottu, Paul
Petrow, Peter
Sastre-Garrau, Xavier
Salmon, Rémy Jacques
Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
title Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
title_full Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
title_fullStr Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
title_full_unstemmed Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
title_short Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
title_sort outcome in advanced ovarian cancer following an appropriate and comprehensive effort at upfront cytoreduction: a twenty-year experience in a single cancer institute
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265260/
https://www.ncbi.nlm.nih.gov/pubmed/22312486
http://dx.doi.org/10.1155/2010/214919
work_keys_str_mv AT marszalekanne outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT alranseverine outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT schollsuzy outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT fourchottevirginie outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT planchercorinne outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT rostychristophe outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT meynieljeanphilippe outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT demargerievincent outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT dorvalthierry outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT delarochefordiereanne outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT cottupaul outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT petrowpeter outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT sastregarrauxavier outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute
AT salmonremyjacques outcomeinadvancedovariancancerfollowinganappropriateandcomprehensiveeffortatupfrontcytoreductionatwentyyearexperienceinasinglecancerinstitute